CRSP CRISPR Therapeutics AG

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business: Development and commercialization of transformative CRISPR/Cas9 gene-editing therapeutics for serious diseases including hemoglobinopathies, in vivo editing, CAR T therapies, and regenerative medicine
• • New emphasis: First approved CRISPR-based therapy CASGEVY launched globally in 2023 for sickle cell disease and beta thalassemia, with ongoing pediatric trial expansions and targeted conditioning research
• • Strategic shift: Increased focus on in vivo editing pipeline using proprietary SyNTase technology and LNP delivery to target liver and other tissues, alongside advancing siRNA programs via Sirius partnership
• • Quantitative metric: CASGEVY approved in multiple countries, addressing an estimated 60,000 patients; pediatric pivotal studies show 100% efficacy in vaso-occlusive crisis and transfusion independence endpoints
• • Noteworthy fact: CASGEVY is the world’s first approved CRISPR-based gene therapy, representing a major milestone and shifting CRISPR Therapeutics from R&D to commercial-stage biopharma firm

Risk Factors

• • Regulatory risk: FDA final guidance "Human Gene Therapy Products Incorporating Human Genome Editing" issued January 2024 may require additional testing or data
• • Macroeconomic threat: Increased CASGEVY development and commercialization costs starting 2025 exceed revenue share, impacting financial position
• • Operational vulnerability: Dependence on third-party manufacturers and supply chain to establish clinical and commercial product supply capacity
• • Competitive risk: Other gene editing firms' ex vivo/in vivo therapies may trigger additional FDA requirements delaying CRISPR Therapeutics’ programs
• • Financial risk: Cash $1,975.8M as of Dec 31, 2025 sufficient for 24 months, but substantial capital raises required thereafter, diluting shareholders

Management Discussion & Analysis

• • No revenue or YoY revenue figures disclosed for 2025 vs 2024
• • Operating cash flow used $345.0M in 2025 vs $142.8M in 2024, $202.2M increase due to timing of Vertex milestone payments
• • Investing cash flow used $31.8M in 2025 vs $280.5M in 2024, improvement driven by marketable debt securities maturities in 2025
• • Financing cash flow provided $426.0M in 2025 vs $332.0M in 2024, mainly from $397.3M ATM common shares sale and $27.7M stock option proceeds
• • Outlook: Cash sufficient to fund operations 24 months; dependency on equity/debt financing; risks include volatile markets, regulatory approval uncertainties, and commercial execution

What are the latest CRSP SEC filings in 2026?

CRISPR Therapeutics AG (CRSP) has filed a 10-K annual report on February 12, 2026, a 10-Q quarterly report on May 4, 2026, an 8-K current report on August 3, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did CRSP file its most recent 10-K annual report?

CRISPR Therapeutics AG (CRSP) filed its most recent 10-K annual report on February 12, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view CRSP 10-Q quarterly reports?

CRISPR Therapeutics AG (CRSP)'s most recent 10-Q quarterly report was filed on May 4, 2026. SignalX displays every CRSP 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has CRSP filed recently?

CRISPR Therapeutics AG (CRSP)'s most recent 8-K was filed on August 3, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find CRSP insider trading activity (Form 4)?

SignalX aggregates every CRSP Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does CRSP file with the SEC?

CRISPR Therapeutics AG (CRSP) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new CRSP filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for CRISPR Therapeutics AG (CRSP).

What is CRSP's SEC CIK number?

CRISPR Therapeutics AG (CRSP)'s SEC CIK (Central Index Key) number is 1674416. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1674416 to look up all CRSP filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find CRSP return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from CRISPR Therapeutics AG (CRSP) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.